VTYX
Ventyx Biosciences, Inc.Company Information
- Company Name
- Ventyx Biosciences, Inc.
- CIK
- CIK0001851194
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- VTYX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- VTYX
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-12-23
- Last sale
- 2025-12-18
- Shares purchased (TTM)
- 130,000
- Shares sold (TTM)
- 96,187
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 50,634,675
- Shares outstanding
- 71,304,084
- Ownership
- 71.01%
Earnings Market Reaction
- Filing date
- 2025-11-06
- Price on filing date
- —
- 1-month reaction
- 7.99%
- 3-month reaction
- 51.51%
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Non Voting Preferred Stock | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 32 | 32 | 28 | 27 | 62 | 41 | 142 | 52 | 57 | 52 | 64 | 65 | ||||||
| Marketable Securities Current | 161 | 177 | 201 | 190 | 213 | 199 | 161 | 201 | 244 | 281 | 313 | 253 | ||||||
| Prepaid Expense And Other Assets | 8 | 10 | 14 | 12 | 15 | 17 | 17 | 12 | 7 | 14 | 10 | 13 | ||||||
| Assets Current | 201 | 219 | 243 | 230 | 289 | 257 | 320 | 264 | 308 | 347 | 387 | 331 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Operating Lease Right Of Use Asset | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 12 | 12 | 1 | 1 | 2 | ||||||
| Marketable Securities Noncurrent | - | - | - | 36 | - | 40 | - | - | - | - | - | 39 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 211 | 230 | 253 | 277 | 301 | 309 | 332 | 278 | 322 | 349 | 389 | 371 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 2 | 3 | 2 | 7 | 6 | 6 | 9 | 4 | 7 | 6 | ||||||
| Accrued Liabilities Current | 9 | 9 | 9 | 9 | 9 | 11 | 8 | 16 | 16 | 16 | 10 | 10 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 11 | 11 | 12 | 13 | 12 | 18 | 15 | 22 | 26 | 20 | 17 | 16 | ||||||
| Operating Lease Liability Noncurrent | 9 | 9 | 9 | 10 | 10 | 10 | 11 | 12 | 12 | 1 | 1 | 1 | ||||||
| Liabilities | 20 | 21 | 22 | 23 | 22 | 28 | 25 | 34 | 38 | 21 | 18 | 18 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 823 | 818 | 813 | 808 | 803 | 771 | 765 | 663 | 657 | 647 | 637 | 581 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 1 | -0 | -0 | -0 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -632 | -609 | -582 | -554 | -525 | -490 | -458 | -419 | -372 | -318 | -265 | -226 | ||||||
| Stockholders Equity | 191 | 209 | 232 | 254 | 279 | 281 | 307 | 244 | 284 | 328 | 372 | 354 | ||||||
| Liabilities And Stockholders Equity | 211 | 230 | 253 | 277 | 301 | 309 | 332 | 278 | 322 | 349 | 389 | 371 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | 900 | ||||||
| Common Stock Shares Issued | 71 | 71 | 71 | 71 | 71 | 71 | 70 | 59 | 59 | 59 | 58 | 57 | ||||||
| Shares Outstanding | 71 | 71 | 71 | 71 | 71 | 71 | 70 | 59 | 59 | 59 | 58 | 57 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialVentyx Biosciences, Inc. (VTYX) — SEC Financial Statements & Analysis
Ventyx Biosciences, Inc. (VTYX) is a pharmaceutical preparations company, incorporated in DE. Ventyx Biosciences, Inc. trades on Nasdaq as: VTYX. Ventyx Biosciences, Inc. (VTYX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-06. Based on that filing, On profitability, Ventyx Biosciences, Inc. posts a Return on Equity (ROE) of -45.35%, a Return on Assets (ROA) of -41.60%, and a Return on Invested Capital (ROIC) of -62.02%. Per share, it reports EPS of $-1.50, diluted EPS of $-1.50, free cash flow per share of $-1.23, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -30.10% year-over-year and EPS growth of -30.73% year-over-year. On the balance sheet, it maintains a current ratio of 17.86x, a quick ratio of 17.86x, working capital of $189.84M, a debt-to-equity ratio of 0.11x, a debt ratio of 0.1, free cash flow of $-87.87M (TTM), and net debt of $-31.97M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-1.50
- ROE TTM
- -45.35%
- ROA TTM
- -41.60%
- Debt To Equity
- 0.11x
- Free Cash Flow TTM
- $-87.87M
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Ventyx Biosciences, Inc. in?
Ventyx Biosciences, Inc. (VTYX) operates in the Pharmaceutical Preparations industry.
What exchange does VTYX trade on?
Ventyx Biosciences, Inc. (VTYX) trades on the Nasdaq.
Where is Ventyx Biosciences, Inc. incorporated?
Ventyx Biosciences, Inc. is incorporated in DE.
When was Ventyx Biosciences, Inc. (VTYX)'s most recent SEC filing?
Ventyx Biosciences, Inc. (VTYX)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-06.
What is VTYX's EPS (earnings per share)?
Ventyx Biosciences, Inc. (VTYX)'s trailing twelve month EPS is $-1.50 as of 2025-09-30.
What is VTYX's ROE (return on equity)?
Ventyx Biosciences, Inc. (VTYX)'s trailing twelve month Return on Equity (ROE) is -45.35% as of 2025-09-30.
What is VTYX's ROA (return on assets)?
Ventyx Biosciences, Inc. (VTYX)'s trailing twelve month Return on Assets (ROA) is -41.60% as of 2025-09-30.
What is VTYX's ROIC (return on invested capital)?
Ventyx Biosciences, Inc. (VTYX)'s trailing twelve month Return on Invested Capital (ROIC) is -62.02% as of 2025-09-30.